← ANALYST RATINGS · TIPRANKS
Avita Medical (RCEL): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $13.67, the highest $15.00, the lowest $12.00. The average is +4.8% from the last price of $13.04.
Analyst ratings 4
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $14.00 → $13.50−3.6% | Hold | +3.5% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $15.00 → $14.50−3.3% | Buy | +11.2% | Upgrade | 17.10.26on TipRanks 07:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $14.00 → $13.50−3.6% | Hold | +3.5% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $13.50 → $14.00+3.7% | Hold | +7.4% | Reiterated | 13.10.26on TipRanks 14:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $14.50 → $15.00+3.4% | Buy | +15.0% | Upgrade | 13.10.26on TipRanks 14:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $13.50 → $14.00+3.7% | Hold | +7.4% | Reiterated | 13.10.26on TipRanks 14:05 | — | |
| Ryan Zimmerman★★★★★★★★★★#3375 · hits 46% · avg +3.3% | BTIG | $11.00 → $15.00+36.4% | Buy | +15.0% | Reiterated | 12.10.26on TipRanks 08:35 | +1.3%next day −0.1% | ↗ |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $14.00 | Hold | +7.4% | Reiterated | 12.10.26on TipRanks 05:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $13.00 | Hold | −0.3% | Reiterated | 12.10.26on TipRanks 05:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $13.50 | Hold | +3.5% | Reiterated | 12.10.26on TipRanks 05:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $13.50 | Hold | +3.5% | Reiterated | 12.10.26on TipRanks 05:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $14.50 | Buy | +11.2% | Upgrade | 12.10.26on TipRanks 05:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $13.50 | Hold | +3.5% | Reiterated | 12.10.26on TipRanks 05:05 | — | |
| Josh Jennings★★★★★★★★★★#3537 · hits 46% · avg +3.0% | TD Cowen | $14.00 | Buy | +7.4% | Reiterated | 17.09.26on TipRanks Sep 18 02:20 | +6.2%next day −1.9% · 5 days +2.4% | ↗ |
| Frank Takkinen★★★★★★★★★★#11823 · hits 38% · avg −3.6% | Lake Street | $12.00 | Buy | −8.0% | Reiterated | 28.08.26on TipRanks 09:00 | +0.5%next day −2.1% · 5 days +8.1% | ↗ |
| Carl Byrnes★★★★★★★★★★#11765 · hits 37% · avg −4.0% | Northland Securities | $10.00 | Buy | −23.3% | Reiterated | 26.03.26on TipRanks 10:25 | −1.5%next day +0.7% · 5 days −5.5% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Avita Medical
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 12.10.26: target $13.67 at a price of $13.21 (+3.5%); now: $13.67 at $13.04 (+4.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 1 | 1 |
| Buy | 4 | 5 | 5 | 8 | 8 | 7 |
| Hold | 3 | 4 | 3 | 2 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.24 (from $-0.30 to $-0.20). Last quarter: $-0.25.
Sales
Next quarter’s sales estimate — $22M (from $22M to $23M). Last quarter: $22M.
Best top-analyst consensus in the sector · Healthcare
About Avita Medical
- CEO: Cary G. Vance
- Employees: 226
- 28159 Avenue Stanford, Valencia, CA, 91355, US
- avitamedical.com
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
Data from the stock’s TipRanks forecast page, read 122 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗